Shots:

• The P-III PROTECTIVE-1 study assessing plinabulin as monothx vs Pegfilgrastimfor in patients with CIN. The US FDA accepted the NDA & PR and the anticipated PDUFA date is Nov 30- 2021
• The trial met its 1EP i.e plinabulin (day 1 dose as CT) demonstrates non-inferiority against Pegfilgrastim- improvement in bone pain- and platelet count. The therapy further supports the reduction of FN- hospitalization @ 1 week- following CT
• Additionally- four studies program includes P-II/III PROTECTIVE-1 & P-II/III PROTECTIVE-2 studies supports the combination regimen of plinabulin and G-CSF to prevent CIN in all solid tumors and CT

Ref: GlobeNewswire | Image: BeyondSpring